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The effect of pretreatment with FK506 on renal is-
chemia and reperfusion (I/R) injury was investigated 
using a rat model. Animals were assigned to one of two 
groups (20 rats each). Group 1 animals (controls) re-
ceived 0.5 ml saline while group 2 animals received 
FK506 (0.3 mg/kg), administered intravenously 24 hr 
prior to the induction of renal ischemia. A 60-min period 
of ischemia of the right kidney was induced, and upon 
reperfusion a left nephrectomy was performed. Blood 
samples for estimation of BUN, creatinine, and tumor 
necrosis factor were collected on days 0 (preischemia), 
1,2,3,5,7, and 10 (postischemia). Rats were sacrificed 
after day 10 and renal tissue was examined histologi-
cally. All animals survived the ischemic episode. FK506 
pretreatment significantly reduced the serum levels of 
BUN (P<0.02), creatinine (P<0.02), and TNF (P<0.05) 
as compared with that seen in controls. Histologically, 
at day 10, the kidneys showed the expected sequelae of 
prior renal I/R with various degrees of tubular damage. 
However, no objective differences were evident between 
the two groups. Based upon these data, it can be con-
cluded that (1) FK506 pretreatment ameliorates the 
functional renal injury associated with I/R, (2) renal 
ischemia induces the release of TNF, and (3) FK506 
pretreatment results in a significant inhibition of TNF 
production. These data suggest that the release of TNF 
may be responsible for the increasing of BUN and cre-
atinine levels seen after renal I/R and that pretreatment 
of renal donors with FK506 may improve renal function 
in the immediate post-transplant period. 
FK506 has been shown to be an effective and safe immuno-
suppressive agent capable of inducing long-term allograft ac-
ceptance in renal transplantation (1, 2)_ Nevertheless, the graft 
injury associated with ischemia and reperfusion (I/R) experi-
enced during organ harvesting and engraftment still poses a 
major problem in clinical renal transplantation. 
In previous experiments, FK506 has been shown, in addition 
to being a potent immunosuppressant, to be a hepatoprotective 
against I/R injury occurring in rats subjected to a sixty-minute 
period of total ischemia of the right hepatic lobe followed by 
resection of the nonischemic median and left hepatic lobes (3-
7). The hepatoprotective effect of FK506 has been related 
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partly to its ability to inhibit the production of several cytokines 
including tumor necrosis factor, a critical early mediator of 
organ injury (7). The purpose of the present study was to 
further extend this issue by examining the effect of FK506 
pretreatment on the renal injury associated with I/R in a rat 
model. 
MATERIALS AND METHODS 
Animals. Male inbred Lewis rats weighing 200-250 g were used for 
all experiments (Harlan-Sprague-Dawley, Indianapolis, IN). All ani-
mals were acclimatized to the Animal Research Lab for one week prior 
to being utilized. They were given free access to food and water both 
before and after the experimental renal ischemia. 
Surgical procedure. Anesthesia was induced and maintained using 
metofane inhalation. A midline abdominal incision was made. The 
right perirenal fascia was dissected free, leaving only the pedicle of 
renal vessels and ureter. The right renal vessels were identified and 
clamped using temporary microvascular clamps, inducing a 60-minute 
period of total ischemia. Upon removal of the clamps and reperfusion 
of the right kidney, a left nephrectomy was performed. All animals 
were allowed to recover spontaneously and survival was observed at 
12-hr intervals for a total of 10 days, after which they were sacrificed. 
Experimental protocol. Animals were randomly assigned to one of 
two different experimental groups consisting of 20 rats each. Group 1 
animals (controls) were injected intravenously with 0.5 ml saline solu-
tion while group two rats received FK506 (0.3 mg/kg in 0.5 ml saline) 
administered intravenously, 24 hr prior to the induction of the experi-
mental renal ischemia. Blood samples for the estimation of blood urea 
nitrogen and creatinine and for the bioassays of circulating TNF were 
collected via the tail vein on days 0 (preischemia), 1, 2, 3, 5, 7, and 10 
(postischemia). No more than three samples were withdrawn from each 
animal, and at each draw the blood withdrawn was immediately re-
placed by an equal volume of lactated Ringer's solution. The serum 
was separated immediately and stored at -20·C until being assayed. 
The animals were weighed at the start and end of the experimental 
period. 
Biochemical analyses and TNF bioassays. In each rat, serum levels 
of BUN and creatinine were determined using standard laboratory 
methods and Sigma diagnostic kits. The measurement of TNF was 
based upon quantitation of the cytolytic activity of TNF in lysing L-
M (murine mouse connective tissue) cells in the presence of actino-
mycin D, as measured by the uptake of crystal violet dye by residual 
viable cells (Genentech Inc, San Francisco, CAl (8). Briefly, L-M cells 
are cultivated in serum-free medium (M199 containing 0.5% bactopep-
tone). Confluent monolayers are detached using sterile glass beads, 
resuspended in M199 supplemented with 0.5% bactopeptone, 100 U/ 
ml penicillin, 100 Itg/ml streptomycin, 1 Itg/ml insulin, and 0.024 M 
Hepes buffer. The cells are then seeded at a density of 4XI0' cell per 
well into a 96-well microtiter plate. Following incubation for 24 hr at 
37·C in a humidified atmosphere with 5% CO2, the medium in the 
wells is replaced with fresh medium containing actinomycin D at a 
final concentration of 1 Itg/ml. The plates are then incubated for an 
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additional 18-20 hr at 37'C and stained with 0.5% crystal violet, 
washed, dried, and read by a plate-reader at 540 nm. Activity levels are 
reported as units/ml, where 1 U /ml equals approximately B.B pg TNF / 
ml. 
Histological studies. At day 10 following renal ischemia and sacrifice, 
the kidneys were fixed in 10% formalin, dehydrated, embedded in 
paraffin, sectioned at 5 JL and stained for histological examination with 
hematoxylin and eosin. Histological variables at day 10 postischemia 
were subjectively scored and compared using a 0-4+ grading system 
where 0 = no regenerative tubules; 1 = 0-25% regenerative tubules, 2 
= 25-50%, 3 = 50-75%, and 4 = 75-100%). Likewise, tubular dilatation, 
which also reflects recovery from tubular damage, was assessed using 
the same scoring system from 0-4+. Other variables such as calcifica-
tion in the renal tubules, vascular vacuolization, vascular thrombosis, 
and evidence of infarcts were also estimated and compared. 
Statistical analysis. Data are reported as the mean and SEM. BUN 
and creatinine data were analyzed using the two-way analysis of vari-
ance to examine the main treatment effects of FK506 and of time 
following ischemia and reperfusion. The possible interaction of the two 
main treatment effects were evaluated. The chi square test was used to 
test for differences in proportions. A P value of <0.05 was considered 
to be significant. 
RESULTS 
All animals survived the ischemic episode. The animals in 
both groups lost weight averaging 8% of their body weight 
during the 10 days of the experiment. No difference between 
groups for weight was evident before or at the end of the 
experimental period. Graphic representations of the time 
courses of the mean serum levels of BVN and creatinine in the 
saline- and FK506-pretreated animals are shown in Figures 1 
and 2, respectively. Serum BVN and creatinine levels in both 
groups were elevated after I/R, peaked at 72 hr and declined 
thereafter toward their preischemic levels at day 10. There was 
a significant effect of pretreatment with FK506 with respect to 
both BVN (P<0.02) and creatinine (P<0.02). 
TNF was measurable in the serum of all experimental ani-
mals after renal ischemia and reperfusion. In contrast, TNF 
was undetectable in the preischemic samples obtained from the 
animals in both groups. The mean peak TNF level in saline-
pretreated controls was 8.66+ 1.8 V Iml with a range of 5.83-
11.98 Vlml and it occurred at 72 hr postischemia. The mean 
peak TNF level was 5.21+0.7 Vlml with a range of 3.1-7.74 VI 
ml in FK506-pretreated rats and it occurred at 48 hr after the 
ischemic episode (Fig. 3). At days 3 and 5 following ischemia, 
the mean value of TNF was significantly lower in the rats 
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FIGURE 1. Serum BUN levels (mg/dl) in the animals studied. The 










• o 2 
oL...--'--",----'---'---J_-'--",----'---'---




----. FK 506 
0.3 mglKg 
FIGURE 2. Serum creatinine levels (mg/dl) in the animals studied. 
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FIGURE 3. Serum TNF levels (U/ml) in the animals studied. The 
points represent the mean level and the brackets indicate the SEM ([*] 
P <0.05). 
icant positive correlation was found between serum TNF levels 
and serum BVN levels (P<0.05) and serum TNF levels and 
creatinine (P<0.05) levels (Figs. 4 and 5, respectively). 
Histologically, kidneys at day 10 showed sequelae of tubular 
damage in both the control and the experimental groups. This 
was manifest by occasional necrotic tubular epithelial cells, 
areas of tubular dilatation, and areas of basophilic regenerative 
epithelium with somewhat predominant nucleoli and occasional 
mitoses. Focal areas of calcification and interstitial widening 
with focal mononuclear infiltrates were seen also in both 
groups. There was no evidence of infarcts or of vascular throm-
bosis in the sections examined. The extent of changes was 
variable within each group, and no objective difference could 
be distinguished between the two groups. Although a trend 
toward less damage was observed in the FK506-pretreated 
group as a whole, it was not possible to tell into which group a 
single case fell on the basis of the histology alone. 
DISCUSSION 
The large increase in the number of organ transplantations 
in recent years has resulted in growing interest in the patho-
physiological events that are associated with ischemia and 
reperfusion injury. 
In previous experiments we have shown the ability of FK506 
pretreatment to ameliorate the hepatic injury associated with 
I/R, as evidenced by improved animal survival (3-7). Improve-
ment in survival was reflected by a restoration of hepatic ATP 
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FIGURE 4. Correlation between mean serum levels ofTNF and BUN 
in saline-pretreated animals (r=0.929, [*] P<0.05) and in FK506-
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FIGURE 5. Correlation between mean serum levels of TNF and 
creatinine in saline-pretreated animals (r=0.90, [*] P<0.05) and in 
FK506-pretreated animals (r=0.82, [*] P<0.05) and in FK506-pre-
treated animals (r=0.82, [*]P<0.05). 
content; a reduction in serum levels of ALT and LDH (5,6), 
as well as TNF and interleukin 6 (7); an amelioration of hepatic 
necrosis and neutrophilic infiltration; and an increase in the 
mitotic activity of the liver (6). A hepatoprotective effect of 
pretreatment with cyclosporine has also been shown by several 
investigators (9, 10). However, a well-known side effect of CsA 
administration is nephrotoxicity (11), which may become more 
pronounced in the presence of a renal ischemic insult (12-16). 
Both experimental (17) and clinical (18) results reported from 
Pittsburgh have shown that FK506 does not have the severe 
pattern of nephrotoxicity found with CsA that leads to renal 
failure and the need for dialysis in some patients (19). 
Currently, it is believed that ischemic renal damage occurs 
in two stages-one that is induced during blood flow interrup-
tion and one that occurs in the immediate reperfusion period 
(20). This concept is supported by the presence of minimal 
histologic damage before the reperfusion process and the pro-
tection conferred by therapeutic interventions imposed during 
early reflow (21, 22). 
Blood flow may be reduced by mechanical obstruction to the 
vascular lumen produced by endothelial swelling (23) or by 
vascular congestion with erythrocytes (trapping) (24, 25) re-
sulting from neutrophil "capillary plugging" (26-28) and/or 
capillary wall injury (29) with consequent "capillary leakage," 
extravasation of plasma, and local hemoconcentration (30, 31). 
This is supported by the finding that renal function improved 
considerably when medullary congestion was reduced by a 
lowering of the hematocrit (32). Alternatively renal vasocon-
striction due to humoral or neural stimuli may be responsible 
for the increase in renal vascular resistance in the first few 
hours following ischemic injury (33). It has also been suggested 
that the depletion of ATP during ischemia, leads to an irre-
versible renal cell damage (5). 
Several mechanisms have been proposed for reperfusion in-
jury. The first is the production of xanthine oxidase-mediated 
free radical production (34, 35). In support of this hypothesis 
is the improvement in renal function by treatment with allo-
purinol (36) or superoxide dismutase (4, 37). The second is 
increased neutrophil adherence to damaged endothelium (38) 
that may intensify injury (39, 40), possibly by exacerbating the 
"no-reflow" phenomenon or by contributing to oxidant damage 
(41). Third, the delivery of calcium during reperfusion to an 
energy-depleted organ may produce cellular calcium overload 
that can exacerbate tissue damage (42). Fourth, the incomplete 
adenine nucleotide recovery in the postischemic period leaves 
the cells relatively energy-deficient (43). 
TNF is produced by activated macrophages, and receptors 
for TNF are present in all somatic cells, with the exception of 
erythrocytes (44). TNF causes augmented neutrophil aggrega-
tion and adherence to endothelial cells (45), increased super-
oxide anion regeneration (46), enhancement of neutrophilic 
phagocytic (47) and cytotoxic activities (48), induction of endo-
thelial production of IL-1 and procoagulant factors, augmen-
tation of lymphocyte production of and response to IL-2, and 
induction of a general shock-like state (44). Thus the vascular 
injury that follows renal I/R may occur as a consequence of the 
action of TNF on endothelial cells and neutrophils. This may 
also explain the presence of TNF during renal allograft rejec-
tion (49). 
In the present study, the data show that FK506 pretreatment 
ameliorates the renal injury associated with I/R, as evidenced 
by a significant reduction in the subsequent BUN and creati-
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nine levels (Figs. 1 and 2, respectively). The results also show 
that, similar to hepatic I/R, TNF production is triggered by 
renal I/R injury and is significantly inhibited by a single dose 
intravenous dose of FK506 (0.3 mg/kg) administered 24 hr 
prior to the induction of renal ischemia (Fig. 3). While the 
precise mode of inhibition of TNF activity by FK506 remains 
unknown, one explanation may be that FK506 has a direct 
effect on macrophages (independent of lymphocytes) or on the 
communication between macrophages and lymphocytes. It is 
conceivable that during I/R either oxidants or oxidant-stimu-
lated proinflammatory factors such as platelet-activating factor 
stimulate lymphocytes to release lymphokines that conse-
quently initiate neutrophil infiltration (50). Since both esA 
(51) and FK506 (52) have been shown to inhibit the release of 
lymphokines (from activated lymphocytes) with chemotactic 
activity for neutrophils it is possible that FK506 modulates 
neutrophil infiltration through its effect on lymphocytes. 
Whether a similar effect upon renal function would be obtain-
able were animals treated with cyclosporine rather than FK506 
prior to I/R is unknown. The results of such an experiment 
would be of considerable interest. Such a group was not included 
in the present study because the investigators were convinced 
that cYclosporine would be overtly nephrotoxic and as such 
would result in needless animal deaths. 
The reversibility of ischemic acute renal failure depends on 
the ability of renal tubular cells to regenerate and replace 
damaged areas of epithelium along the nephrons (53). It is 
conceivable that ischemic renal injury may activate a cytotoxic 
immune reaction against renal tubular cells and other cells 
present in the kidney, as a consequence of an induced structural 
alteration caused by ischemia, and thereby impair the ability 
of the renal tubular cells to regenerate. Such an action might 
be unmasked by the powerful T cell-specific immunosuppres-
sion exhibited by FK506. A further possible mechanism for the 
protective effect of FK506 herein observed is through restora-
tion of cellular ATP levels following renal I/R-an action 
similar to its effect in the case of hepatic I/R (6) that needs 
further investigation. 
No discernible differences were observed histologically with 
light microscopy at day 10 postischemia in saline- and FK506-
pretreated animals, which is consistent with the decline toward 
the baseline of BUN, creatinine, and TNF levels at day 10 in 
both groups. Had a more precise measure of renal function 
such as insulin clearance been performed as part of the present 
study, evidence for a long-lasting effect of FK506 as compared 
with saline-treated controls might have been seen. 
Nonetheless, from the data presented, it can be concluded 
that FK506 pretreatment ameliorates the acute renal injury 
associated with I/R, as demonstrated by the decrease in BUN 
and creatinine levels over a lO-day period; renal I/R induces 
the release of TNF; there is a positive correlation between TNF 
levels and BUN and TNF levels and creatinine; and FK506 
pretreatment results in a significant inhibition of TNF produc-
tion. Based upon these data, it can be speculated that the 
release of TNF may be responsible, at least in part, for the 
increase in BUN and creatinine levels seen after I/R and that 
pretreatment of renal donors with FK506 may be associated 
with improvement in immediate posttransplant function. Such 
a speculation merits further evaluation. 
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